Biological Products, (No Diagnostic Substances)·PL VENLO
Summary Financials
QIAGEN N.V. — SlamSEC
Revenue
$2.1B
-4.9% YoY
FY 2024
Adj. EBITDA
$739.9M
34.5% margin
FY 2024
Net Income
$423.2M
19.8% margin
FY 2024
EPS (Diluted)
$1.84
FY 2024
Stock Price
$40.92
+0.8%
2026-03-16
52W Range
$39.94 – $57.81
P/E Ratio
22.2x
Market Cap
$9.1B
Cash
$668.1M
FY 2024
Total Debt
$1.1B
FY 2024
Net Debt
$396.1M
FY 2024
Enterprise Value
$9.5B
Debt / EBITDA
0.5x
FY 2024
EV / EBITDA
12.8x
Employees
6K
FY 2024
V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research.